(Q54493173)

30 May 2018

title

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. (English)

1 reference

30 May 2018

gastrointestinal stromal tumor

main subject

biomarker

0 references

patient

0 references

1 reference

S George

1

1 reference

30 May 2018

P Reichardt

2

1 reference

30 May 2018

T Lechner

3

1 reference

30 May 2018

S Li

4

1 reference

30 May 2018

D P Cohen

5

1 reference

30 May 2018

G D Demetri

6

1 reference

30 May 2018

publication date

2 August 2012

1 reference

30 May 2018

published in

Annals of Oncology

1 reference

30 May 2018

volume

23

1 reference

30 May 2018

issue

12

1 reference

30 May 2018

page(s)

3180-3187

1 reference

30 May 2018

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Rapid development of hypertension by sorafenib: toxicity or target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Hypertension as a surrogate marker for the activity of anti-VEGF agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Sunitinib for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Molecular pathobiology of gastrointestinal stromal sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Vascular endothelial growth factor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS179

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS179

1 reference

30 May 2018

PubMed ID

22858558

1 reference

30 May 2018